Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.
 
Per the terms of the agreement, Scenic Biotech will be entitled to an upfront payment and potential additional payments contingent upon achievement of a range of research, development and commercial milestones. No further financial details have been disclosed.
 
“Working with a world leader in drug discovery and development is an important validation of our Cell-Seq platform’s unique capability to link cellular pathways to drug targets,” commented Oscar Izeboud, PhD, CEO of Scenic Biotech. “As we continue to advance our own pipeline of first-in-class disease-modifying therapies, we remain committed to harnessing the power of our ground-breaking approach to support our collaborators in crafting innovative medicines for patients with devastating conditions.”
 
The collaboration with Bristol Myers Squibb marks Scenic Biotech’s second strategic collaboration with a major industry partner, following the multi-year genetic modifier collaborative agreement with Genentech announced in 2020. Both collaborations leverage the Cell-Seq platform’s ability to provide genetic insights leading to the discovery and development of novel therapeutics.